Trial reportFrontiers in immunology2022
Complement-mediated serum bactericidal activity of antibodies elicited by the
Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study.The Journal of infectious diseases · 2024Trial
- Review
- Vaccine-induced antibodies can limitmBio · 2026Article
- Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives.Vaccines · 2025Review
- Protein-specific immune response elicited by themSphere · 2025Article
- Article
- High-Throughput Luminescence-Based Serum Bactericidal Assay Optimization and Characterization to Assess Human Sera Functionality Against MultipleInternational journal of molecular sciences · 2024Article
- Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine.NPJ vaccines · 2024Article
- Oral immunization withmSphere · 2024Article
- Development of a visual Adhesion/Invasion Inhibition Assay to assess the functionality ofFrontiers in immunology · 2024Article
- Outer Membrane Vesicle Vaccine Platforms.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Age-dependent acquisition of IgG antibodies toFrontiers in immunology · 2024Article
- A next-generation GMMA-based vaccine candidate to fight shigellosis.NPJ vaccines · 2023Article
- The Two Faces of Bacterial Membrane Vesicles: Pathophysiological Roles and Therapeutic Opportunities.Antibiotics (Basel, Switzerland) · 2023Review
- Toward aInternational journal of molecular sciences · 2023Review
- Exploring the Role of GMMA Components in the Immunogenicity of a 4-Valent Vaccine againstInternational journal of molecular sciences · 2023Article
- Functional assays to evaluate antibody-mediated responses againstFrontiers in cellular and infection microbiology · 2023Review
- Comparison ofFrontiers in molecular biosciences · 2023Article
- Editorial: Pattern recognition receptors at the crosstalk between innate and adaptive immune systems and implications for vaccine development.Frontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.